Physician profile
Sergey Turchin
NPI 1033177878
$459.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.68 · 2022: $57.69 · 2023: $296 · 2024: $92.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $102.45 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $78.06 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $54.39 | 2022-2023 | Wegovy |
| Amgen INC. | $52.82 | 2023-2024 | Otezla, Repatha |
| Abbvie INC. | $31.08 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $23.71 | 2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $21.09 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.58 | 2024 | |
| Radius Health, INC. | $16.97 | 2023 | Tymlos |
| Shield Therapeutics INC | $16.06 | 2023 | Accrufer |
| Lucid Diagnostics INC. | $15.73 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $15.72 | 2023 | Breztri |
| Amarin Pharma, INC. | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Turchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.